GIP Receptor Antagonist Studies in Humans

Involvement of Glucose-dependent Insulinotropic Polypeptide (GIP) in Human Physiology and Pathophysiology - Receptor Antagonist Studies in Humans

Antagonizing GIP effects during hyperglycaemia in healthy subjects and measurements of insulin secretion.

Aim: To evaluate the GIP receptor antagonizing effect of peptide-based competitive GIP receptor antagonist GIP-A (vs. saline (placebo)) in 10 healthy subjects during 1 hour hyperglycaemic clamps with and without concomitant iv infusion of GIP[1-42]. The intention is to establish GIP-A as a tool to eliminate glucose-dependent insulinotropic GIP signalling.

The study consists of four experimental days (A-D) with assessment of beta cell function during 12 mM-hyperglycaemic clamps with concomitant infusions of A) GIP[1-42], B) GIP-A, C) GIP[1-42] + GIP-A, or D) saline (placebo).

Inclusion Criteria:

• Normal kidney function, liver function and hemoglobin levels.

Exclusion Criteria:

• Medication, Diabetes type 1 or 2, BMI > 25, first degree relatives with Type 2 Diabetes